You're not imagining it. And you're not stuck with it.

Usually by pattern rather than by a single test. Perimenopause can begin in your forties — occasionally earlier — and often starts years before your periods become irregular. Hormone levels swing week to week during this phase, so one blood draw can look reassuringly normal while you feel anything but. That is why we test broadly, interpret results against your symptoms rather than in isolation, and re-test over time instead of drawing a conclusion from a single snapshot.

Those headlines came from the Women's Health Initiative in 2002, and they changed practice almost overnight. What the reanalysis since has shown is that risk depends enormously on who is treated, when, and with what. For healthy women with bothersome symptoms who begin therapy under about age 60, or within roughly ten years of menopause, the balance of benefit and risk is generally favorable. For women starting much later, or with certain histories, it is not. Hormone therapy does carry real risks — stroke, blood clots, and with longer combined use, breast cancer. The point is not that it is safe or unsafe in the abstract. The point is that it is a decision that has to be made about you specifically, with your history and your labs in front of the physician making it.

Possibly, and we will tell you honestly. The evidence supports starting within about ten years of menopause or before age 60. Beginning systemic hormone therapy well outside that window shifts the risk calculation, particularly for cardiovascular risk. That does not mean nothing can be done — localized vaginal estrogen for genitourinary symptoms has a very different and much more favorable risk profile at any age, and much of what drives how you feel is metabolic, not hormonal. We would rather find you the right answer than sell you the one you came in asking for.

Yes, and we should be precise about the word, because it is heavily marketed and widely misunderstood. Bioidentical simply means the molecule is structurally identical to what your body makes. Several bioidentical options — estradiol and micronized progesterone among them — are FDA-approved, manufactured to a consistent dose, and well studied. Custom-compounded 'bioidentical' preparations are a different thing: not FDA-approved, not dose-verified batch to batch, and not supported by the same evidence, despite often being marketed as more natural. Our default is FDA-approved bioidentical formulations. We use compounded preparations only when there is a specific clinical reason, and we will tell you plainly when that is the case.

It has a legitimate but narrower role than the internet suggests. The best evidence supports low-dose testosterone for postmenopausal women with genuinely distressing low sexual desire, after other causes have been addressed. It is worth knowing that there is currently no testosterone product approved by the FDA specifically for women in the United States, so any use is off-label and requires careful dosing and monitoring. We are willing to have that conversation. We are not willing to hand out male-range doses to women, which is a real pattern in this industry and causes real harm.

Often it is not, and if you have a gynecologist who is engaged with menopause care, that is a good thing and we will say so. What we add is depth of testing and continuity of monitoring: a comprehensive metabolic, thyroid, and cardiovascular panel alongside hormones, longer appointments, and a physician following the same numbers over time rather than at an annual visit. Menopause care sits at the intersection of hormones, metabolism, bone, and cardiovascular risk, and it rewards being looked at as one picture.